Back to Evidence

Statistical Appraisal of Crohn's Probiotic Research for Evidence Reviewers | QSevidence 2026

Evidence-Based Medicine20 min read

Statistical appraisal of Crohn's probiotic research begins with study identity and traceable evidence.

Statistical Appraisal of Crohn's Probiotic Research for Evidence Reviewers | QSevidence 2026

For gastroenterology researchers, pharmacists, statisticians and reviewers, QSevidence can help organize literature leads, review questions and professional checks so that methodological judgments rest on verifiable information rather than assumptions.

Verify the design before diagnosing errors

The opened SinoMed record for the study of live Bacillus licheniformis capsules and intestinal function in Crohn's disease describes retrospective inclusion of 107 patients. Treatment-based groups comprised 57 receiving adjunctive capsules with mesalazine and 50 receiving mesalazine. The visible abstract describes retrospective research, not randomized allocation.

This changes the review framework. Treatment selection and confounding require attention; randomized-sequence or allocation-concealment requirements cannot simply be imposed as violations. Access was limited to an indexed abstract, without complete statistical tables, an analysis plan or individual data. Repeated t-tests, distributional misuse and specific misinterpretations of P values are therefore questions to verify, not established errors attributed to this paper.

This is descriptive literature checking and an appraisal proposal, not completed reanalysis or a determination of efficacy. The phrase ai clinical decision support platform denotes an organizational workflow here, not automated verification of every analysis or a prescribing recommendation.

A four-layer register with evidence locations

Review design and baseline information, descriptive summaries, tests and models, and interpretation. Keep each question, required material, source location, rationale and assessment status separate. Use verified, insufficient reporting, data verification needed, or not applicable instead of treating unseen information as an error.

Proposed appraisal register
LayerExtraction fieldsKey distinction
DesignGrouping, time zero, activity, concomitant careConfounding versus randomized-trial requirements
MeasurementScale, range, direction, distribution, error barsUnclear reporting versus demonstrated mismatch
AnalysisUnit, visits, covariates, missingness, multiplicityBetween-group effect versus within-group change
InferenceEstimate, interval, P value, clinical threshold, follow-upStatistical evidence, importance and causation

Two reviewers could extract independently, with clinical and statistical adjudication and documented revisions. This is proposed work: no agreement statistic or error prevalence has been measured. A single paper would not represent statistical quality throughout probiotic research.

Observational comparability is not a baseline P-value certificate

Candidate fields include age, disease duration and activity, location, previous and concurrent medicines, encounter dates and treatment-selection reasons. Availability requires full-text and data checking. Align eligibility, grouping and follow-up time zero, especially the timing of adjunct initiation, so that post-treatment information is not mislabeled as baseline.

The STROBE cohort checklist supports reporting of selection, confounding, missingness and adjusted estimates. It is not a quality score or a conversion of adjusted associations into causal effects. Regression or propensity-score approaches could be considered with justified covariates, overlap and balance assessment, model limitations and residual-confounding discussion.

A genuinely randomized trial needs a different framework. The CONSORT 2025 explanation discourages significance testing of randomized baseline differences and emphasizes prognostic relevance and imbalance magnitude. In either design, baseline P values above 0.05 do not prove comparability or provide a sufficient covariate-selection rule.

Avoid replacing one mechanical rule with another

Intestinal function, pain, stool frequency, inflammation and microbial abundance may involve different scales, boundaries and distributions. First establish what was actually measured. A disease label does not establish non-normality, and possible skewness does not prove a test invalid. Means and standard deviations can describe non-normal data, although they may inadequately convey pronounced asymmetry.

Assess plots, outliers, sample size, model residuals and the estimand. An unreported normality test does not establish failure, and one normality-test P value should not determine the entire analysis. Medians and quartiles may supplement skewed summaries; a few ordered categories can be reported as counts and proportions. Distinguish individual variability from uncertainty around an estimate.

The NIST two-sample t-test explanation distinguishes paired from independent data and equal from unequal variances. Welch methods do not require equal group variances, so a universal equal-variance requirement for every t-test is inaccurate. Rank procedures also do not automatically test a mean or median difference; their interpretation must match the scientific question and assumptions.

Repeated measurements and multiplicity are separate issues

If full text contains multiple visits, identify patient-level repetition and within-person correlation. Significance of change within each arm does not directly test a difference in changes between arms. Repeated records are not additional independent patients. No particular visit schedule has been verified here, so hypothetical week numbers are not reported as study facts.

Depending on outcome scale and target effect, assess baseline-adjusted models, mixed models or generalized estimating equations, including correlation structure, diagnostics and missing-data handling. A single model does not automatically control multiplicity across outcomes, visits and subgroups. Define the primary outcome, comparison and hypothesis family before selecting a control strategy; retain exploratory labels.

Separate unmeasured visits, loss to follow-up, discontinuation and uninterpretable results. Report available denominators and consider relationships between missingness, illness and treatment. Complete-case deletion or arbitrary replacement can change the analyzed population. Explain assumptions behind imputation and sensitivity analyses rather than treating method names as justification.

Separate P values, clinical remission and causality

The ASA official P-value guidance explains that P values measure neither effect magnitude nor the probability a hypothesis is true. Threshold crossing alone should not determine conclusions. A value above 0.05 establishes neither equivalence nor ineffectiveness; a smaller value establishes neither clinical importance nor causation.

Extract definitions, direction, group denominators, effect estimates and 95% confidence intervals. Risk differences, risk ratios, odds ratios and hazard ratios have distinct meanings. Changes in Crohn's activity scores, response criteria and clinical remission also differ. Verify scale-specific and protocol-based thresholds rather than supplying unconfirmed cutoffs.

Equivalence or noninferiority requires a justified prespecified margin and appropriate design and analysis, not retrospective reinterpretation of non-significance. Associations between microbiota and symptoms remain associations; concurrent treatment, activity and sampling may affect interpretation. Appraisal should neither advertise efficacy nor declare ineffectiveness from a reporting gap.

A reproducible professional review workflow

Use QSevidence to organize retrieval, comparison, synthesis, source tracing and professional review. Match study identity first, obtain available full text and supplements, build the register, and seek joint statistical and gastroenterology review. Preserve output, source locations, human edits and access restrictions; assume neither universal database access nor raw-data reanalysis capability.

A future multi-paper project could prespecify its publication window, search and deduplication, eligibility, design strata, error definitions and adjudication before estimating issue frequencies and review time. Current work establishes an identity check and appraisal framework, not the direction or magnitude of bias in the target study.

Frequently asked questions

How can QSevidence support design verification?

Organize title, author, abstract and full-text matches to locate grouping and chronology. Professionals classify observational versus randomized research before choosing an appraisal framework.

How can QSevidence support statistical error appraisal?

Organize methods, scales, effect reporting and source locations into verification questions. Statisticians use actual data and analysis goals to distinguish incomplete reporting from confirmed errors.

How can teams evaluate QSevidence-assisted review?

Assess traceability, extraction accuracy, professionally reviewed revisions and time, retaining disagreements and unresolved questions. Evaluate workflow performance separately from drug efficacy.

Evidence classification and research notice

Sources checked on October 29, 2026 comprise a limited indexed abstract, reporting guidance for observational and randomized research, NIST methods guidance and ASA principles. Access to the target full text and completed reanalysis are not claimed. This article supports methods education and appraisal, not individual prescribing or an efficacy promise for Bacillus licheniformis in Crohn's disease. Qualified professionals retain clinical and research responsibility.